Top MPN specialist John Mascarenhas, MD of Mt. Sinai, talks about the key emerging treatments in clinical trials, as well as recently approved drugs like pacritinib or Vonjo. Dr. Mascarenhas also covers more vulnerable patient groups, including myelofibrosis patients who haven’t responded to a JAK inhibitor (ruxolitinib), addressing imetelstat and reported common side effects.

Featuring: John Mascarenhas, Dir., Adult Leukemia Program, Tisch Cancer Institute, Mt. Sinai & Professor, Icahn School of Medicine

Full story & transcript → Updated Soon at www.ThePatientStory.com

The interview has only been edited for clarity.

Join Our Community:
Website : [ Ссылка ]
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
____________________________
Contents Of This Video:
00:00 - intro
00:40 - The Road to Pacritinib's Approval (Vonjo)
3:18 - Pacritinib - Full Dose - More Effective
4:29 - Current study for MF patients who don't respond to a JAK inhibitor (ruxolitinib)
7:43 - Imetelstat reported side effects
9:26 - How long until MF patients can see imetelstat in real world (FDA approval) ?
11:10 - Top takeaway message for MPN patients and caregivers
____________________________

#ThePatientStory #myeloma #MPN #Cancerexperts #Oncologists #Cancerstories #doctors #Myelofibrosis #PolycythemiaVera #EssentialThrombocythemia

свернуть